Literature DB >> 27829150

Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity.

Tony T Jiang1, Tijana Martinov2, Lijun Xin3, Jeremy M Kinder1, Justin A Spanier2, Brian T Fife4, Sing Sing Way5.   

Abstract

Self-reactive CD4 T cells are incompletely deleted during thymic development, and their peripheral seeding highlights the need for additional safeguards to avert autoimmunity. Here, we show an essential role for the coinhibitory molecule programmed death-1 (PD-1) in silencing the activation of high-affinity autoreactive CD4 T cells. Each wave of self-reactive CD4 T cells that escapes thymic deletion autonomously upregulates PD-1 to maintain self-tolerance. By tracking the progeny derived from individual autoreactive CD4 T cell clones, we demonstrate that self-reactive cells with the greatest autoimmune threat and highest self-antigen affinity express the most PD-1. Reciprocally, PD-1 deprivation unleashes high-affinity self-reactive CD4 T cells in target tissues to exacerbate neuronal inflammation and autoimmune diabetes. Reliance on PD-1 to actively maintain self-tolerance may explain why exploiting this pathway by cancerous cells and invasive microbes efficiently subverts protective immunity, and why autoimmune side effects can develop after PD-1-neutralizing checkpoint therapies.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cell activation; autoimmunity; costimulation; peripheral immune tolerance

Mesh:

Substances:

Year:  2016        PMID: 27829150      PMCID: PMC5108556          DOI: 10.1016/j.celrep.2016.10.042

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  62 in total

1.  An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro.

Authors:  W Rees; J Bender; T K Teague; R M Kedl; F Crawford; P Marrack; J Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide.

Authors:  M S Jordan; A Boesteanu; A J Reed; A L Petrone; A E Holenbeck; M A Lerman; A Naji; A J Caton
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 3.  Age-dependent influences on the origins of autoimmune diabetes: evidence and implications.

Authors:  R David G Leslie; Michela Delli Castelli
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

4.  Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.

Authors:  Hans Christian Probst; Kathy McCoy; Taku Okazaki; Tasuku Honjo; Maries van den Broek
Journal:  Nat Immunol       Date:  2005-01-30       Impact factor: 25.606

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Selective priming and expansion of antigen-specific Foxp3- CD4+ T cells during Listeria monocytogenes infection.

Authors:  James M Ertelt; Jared H Rowe; Tanner M Johanns; Joseph C Lai; James B McLachlan; Sing Sing Way
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Indira Guleria; Arezou Khosroshahi; Tanuja Chitnis; Jaime Imitola; Miyuki Azuma; Hideo Yagita; Mohamed H Sayegh; Samia J Khoury
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

8.  Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice.

Authors:  Cécile Delarasse; Philippe Daubas; Lennart T Mars; Csaba Vizler; Tobias Litzenburger; Antonio Iglesias; Jan Bauer; Bruno Della Gaspera; Anna Schubart; Laurence Decker; Dalia Dimitri; Guy Roussel; Andrée Dierich; Sandra Amor; Andre Dautigny; Roland Liblau; Danielle Pham-Dinh
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Intraclonal competition limits the fate determination of regulatory T cells in the thymus.

Authors:  Jhoanne L Bautista; Chan-Wang J Lio; Stephanie K Lathrop; Katherine Forbush; Yuqiong Liang; Jingqin Luo; Alexander Y Rudensky; Chyi-Song Hsieh
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

10.  CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors.

Authors:  Lokesh A Kalekar; Shirdi E Schmiel; Sarada L Nandiwada; Wing Y Lam; Laura O Barsness; Na Zhang; Gretta L Stritesky; Deepali Malhotra; Kristen E Pauken; Jonathan L Linehan; M Gerard O'Sullivan; Brian T Fife; Kristin A Hogquist; Marc K Jenkins; Daniel L Mueller
Journal:  Nat Immunol       Date:  2016-02-01       Impact factor: 25.606

View more
  26 in total

Review 1.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 2.  [The pathology of adverse events with immune checkpoint inhibitors].

Authors:  V H Koelzer; K Glatz; L Bubendorf; A Weber; A Gaspert; G Cathomas; A Lugli; A Zippelius; W Kempf; K D Mertz
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

3.  PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation.

Authors:  Alessandra Petrelli; Gerdien Mijnheer; David P Hoytema van Konijnenburg; Maria M van der Wal; Barbara Giovannone; Enric Mocholi; Nadia Vazirpanah; Jasper C Broen; Dirkjan Hijnen; Bas Oldenburg; Paul J Coffer; Sebastian J Vastert; Berent J Prakken; Eric Spierings; Aridaman Pandit; Michal Mokry; Femke van Wijk
Journal:  J Clin Invest       Date:  2018-08-02       Impact factor: 14.808

4.  Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes.

Authors:  Tijana Martinov; Linnea A Swanson; Elise R Breed; Christopher G Tucker; Alexander J Dwyer; Jenna K Johnson; Jason S Mitchell; Nathanael L Sahli; Joseph C Wilson; Lovejot M Singh; Kristin A Hogquist; Justin A Spanier; Brian T Fife
Journal:  J Immunol       Date:  2019-07-19       Impact factor: 5.422

Review 5.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 6.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

7.  Opposing peripheral fates of tissue-restricted self antigen-specific conventional and regulatory CD4+ T cells.

Authors:  Zimeng Zhang; Francois P Legoux; Spencer W Vaughan; James J Moon
Journal:  Eur J Immunol       Date:  2019-10-14       Impact factor: 5.532

Review 8.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937

Review 9.  The Role of Programmed Death-1 in Type 1 Diabetes.

Authors:  Brian T Fife; Tijana Martinov; Christopher G Tucker; Alexander J Dwyer
Journal:  Curr Diab Rep       Date:  2021-05-06       Impact factor: 5.430

10.  Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance.

Authors:  Michelle L Miller; Christine M McIntosh; Jason B Williams; Ying Wang; Maile K Hollinger; Noel J Isaad; James J Moon; Thomas F Gajewski; Anita S Chong; Maria-Luisa Alegre
Journal:  Cell Rep       Date:  2018-08-21       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.